Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZY4R2
|
|||
| Drug Name |
JNJ-74699157
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Janssen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | KRAS G12C mutant (KRAS G12C) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04006301) First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation. U.S. National Institutes of Health. | |||
| REF 2 | KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 2020 Sep;89:102070. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.